Cellegy reports positive Tostrelle data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy has begun preparations to move its testosterone gel product Tostrelle into Phase III following discussions with FDA and a positive interim analysis of a Phase II trial in postmenopausal women with low testosterone levels and sexual dysfunction symptoms. The 103-patient, four-month study showed a 65% improvement in number of satisfying sexual events (a 30% increase over placebo). Serum testosterone levels were also brought into normal physiologic range (p<0.001). Cellegy has halted enrollment in the Phase II trial...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.